[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100625213":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":30,"locations":25,"responsibleParty":36,"collaborators":25,"id":38,"slug":39,"hasResults":40,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":25,"eligibilityCriteria":44,"healthyVolunteers":40,"sex":45,"minAge":46,"maxAge":47,"enrollmentInfo":48,"targetDuration":25,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":25,"overallStatus":58,"whyStopped":25,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":25},{"fullName":5,"class":6},"Nazarbayev University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Grape Polyphenol Concentrate","EXPERIMENTAL","Participants receive a grape polyphenol concentrate (QAYNAR) at a dose of 15 mL orally once daily for 3 months, starting with anthracycline- and\u002For trastuzumab-based chemotherapy.",[13],"Dietary Supplement: Grape Polyphenol Concentrate",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Participants receive placebo (dark grape juice) at a dose of 15 mL orally once daily for 3 months, starting with anthracycline- and\u002For trastuzumab-based chemotherapy.",[19],"Other: Placebo (Dark Grape Juice)",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DIETARY_SUPPLEMENT","Grape polyphenol concentrate, 20 mg\u002FmL; participants take 15 mL orally once daily for 3 months starting with chemotherapy.",[9],null,{"type":6,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Placebo (Dark Grape Juice)","Placebo (dark grape juice); participants take 15 mL orally once daily for 3 months starting with chemotherapy.",[15],[31],{"name":32,"role":33,"phone":34,"phoneExt":25,"email":35},"Mohamad Aljofan, PhD","CONTACT","+77054448869","mohamad.aljofan@nu.edu.kz",{"type":37,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100625213","grape-polyphenols-for-prevention-of-chemotherapy-induced-cardiotoxicity-100625213",false,"NCT07419711","Grape Polyphenols for Prevention of Chemotherapy-Induced Cardiotoxicity","Cardioprotective Effects of Grape Polyphenols to Reduce Chemotherapy-Induced Cardiotoxicity in Breast Cancer Patients: A Randomized Pilot Study","Inclusion Criteria:\n\n* Female patients aged 30 to 75 years.\n* Histologically confirmed breast cancer.\n* Planned treatment with anthracycline- and\u002For trastuzumab-based chemotherapy.\n* High or very high risk of chemotherapy-induced cardiotoxicity (≥20%), based on clinical assessment.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-3.\n* Ability to take oral study products.\n* Willingness to comply with study procedures and follow-up visits.\n* Written informed consent provided prior to any study procedures.\n\nExclusion Criteria:\n\n* ECOG performance status of 4.\n* Pre-existing severe cardiovascular disease that would interfere with study participation.\n* Permanent atrial fibrillation or other clinically significant arrhythmias.\n* Severe hepatic or renal impairment.\n* Active central nervous system tumors or metastases.\n* Uncontrolled arterial hypertension.\n* Acute gastrointestinal diseases that may impair absorption.\n* Known allergy or intolerance to grape products or study components.\n* Participation in another interventional clinical trial that may interfere with the outcomes of this study.","FEMALE","30 Years","75 Years",{"count":49,"type":50},120,"ESTIMATED","INTERVENTIONAL",[53],"NA","This pilot randomized clinical study aims to evaluate the cardioprotective effects of a grape polyphenol concentrate in patients receiving anthracycline- and\u002For trastuzumab-based chemotherapy. Adult patients at high or very high risk of chemotherapy-induced cardiotoxicity will be randomized to receive either a grape polyphenol concentrate or placebo for three months, starting with chemotherapy. Cardiac function and cardiotoxicity will be assessed using echocardiographic parameters and circulating biomarkers at baseline, 3 months, and 6 months.",[56,57],"Chemotherapy-induced Cardiotoxicity","Breast Cancer","NOT_YET_RECRUITING","2026-02-16",{"date":61,"type":62},"2026-02-19","ACTUAL",{"date":64,"type":50},"2026-02-09",{"date":66,"type":50},"2027-11-01",{"name":5,"class":6}]